Recent examples include NTRK fusions (e.g., 0.5–4% of colorectal cancer), ROS1 (1–2% of Non-small-cell lung carcinoma), and ALK (~4% of Non-small-cell lung carcinoma), all of which have therapeutics currently in the clinic1–3. Here, ALK is linked to non-small cell lung carcinoma.